Adaptimmune Therapeutics Plc
(OTC) ADAPY
Adaptimmune Therapeutics Plc Financials at a Glance
Market Cap
$5.30M
Revenue (TTM)
$65.08M
Net Income (TTM)
$169.76M
EPS (TTM)
$-0.66
P/E Ratio
-0.03
Dividend
$0.00
Beta (Volatility)
1.20 (Average)
Dividend
$0.00
Beta (Volatility)
1.20 (Average)
Price
$0.02
Volume
735,772
Open
$0.01
Price
$0.02
Volume
735,772
Open
$0.01
Previous Close
$0.02
Daily Range
$0.01 - $0.02
52-Week Range
$0.00 - $0.36
Dividend
$0.00
Beta (Volatility)
1.20 (Average)
Price
$0.02
Volume
735,772
Open
$0.01
Previous Close
$0.02
Daily Range
$0.01 - $0.02
52-Week Range
$0.00 - $0.36
ADAPY News
ADAPY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Adaptimmune Therapeutics Plc
Industry
Biotechnology
Sector
Health CareEmployees
506
CEO
Adrian Rawcliffe
Website
www.adaptimmune.comHeadquarters
Abingdon, OX14 4RX, GB
ADAPY Financials
Key Financial Metrics (TTM)
Gross Margin
86%
Operating Margin
-6%
Net Income Margin
-6%
Return on Equity
-1341%
Return on Capital
-2%
Return on Assets
-1%
Earnings Yield
-33.33%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.30M
Shares Outstanding
265.05M
Volume
735.77K
Short Interest
0.00%
Avg. Volume
741.78K
Financials (TTM)
Gross Profit
$177.96M
Operating Income
$68.76M
EBITDA
$52.66M
Operating Cash Flow
$73.21M
Capital Expenditure
$2.72M
Free Cash Flow
$75.93M
Cash & ST Invst.
$151.60M
Total Debt
$74.21M
Adaptimmune Therapeutics Plc Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$13.68M
-89.3%
Gross Profit
$11.18M
-91.1%
Gross Margin
81.71%
N/A
Market Cap
$5.30M
N/A
Market Cap/Employee
$10.48K
N/A
Employees
506
N/A
Net Income
$30.34M
-143.6%
EBITDA
$26.26M
-137.0%
Quarterly Fundamentals
Net Cash
$22.62M
-113.5%
Accounts Receivable
$28.89M
+21.6%
Inventory
$11.41M
N/A
Long Term Debt
$44.17M
+5.0%
Short Term Debt
$9.03M
-14.7%
Return on Assets
-1.16%
N/A
Return on Invested Capital
-1.89%
N/A
Free Cash Flow
$34.85M
-174.7%
Operating Cash Flow
$34.78M
-173.4%